



1 **Activities, services or aspects of care covered by the**  
2 **guideline update**

3 We will consider making recommendations or updating existing  
4 recommendations on:

- 5 • MRI and biopsy
- 6 • risk-stratified protocol for active surveillance
- 7 • high-intensity focused ultrasound
- 8 • systemic anticancer therapy for non-metastatic prostate cancer
  - 9 – androgen deprivation therapy (ADT)
  - 10 – docetaxel
  - 11 – abiraterone
- 12 • management options after radical treatment for people with non-metastatic  
13 prostate cancer and high-risk features for recurrence.

14 Recommendations that are being retained from the current guideline may be  
15 revised to update language, reflect current policy or practice, and to ensure  
16 consistency with new content.

## 1 **What this guideline update will not cover**

2 This guideline update will not cover:

- 3 • referral from primary care with suspected prostate cancer – this is covered  
4 by NICE’s guideline on suspected cancer: recognition and referral (NG12,  
5 2026)
- 6 • screening for prostate cancer – this is covered by the UK National  
7 Screening Committee.

## 8 **Draft review questions**

9 We have developed the following draft review questions. These may change  
10 during guideline development, but the areas covered will remain as listed in  
11 the final scope.

12 The areas covered and draft questions will be used to develop more detailed  
13 review protocols.

## 14 **MRI and biopsy**

- 15 1. What is the clinical and cost effectiveness of biparametric MRI vs  
16 multiparametric MRI for diagnosing prostate cancer?
- 17 2. What is the clinical and cost effectiveness of local anaesthetic  
18 transperineal prostate (LTP) biopsy vs transrectal ultrasound-guided  
19 (TRUS) biopsy for diagnosing clinically significant prostate cancer?

## 20 **Risk-stratified protocol for active surveillance**

- 21 3. What is the clinical and cost effectiveness of risk-stratified active  
22 surveillance protocols (which may include digital rectal examination)  
23 versus standard care for people with localised prostate cancer?

## 24 **High-intensity focused ultrasound**

- 25 4. What is the clinical and cost effectiveness of high-intensity focused  
26 ultrasound for people with localised prostate cancer?

1 **Systemic anticancer therapy for non-metastatic prostate**  
2 **cancer**

- 3 5. Which people with non-metastatic prostate cancer benefit from a  
4 combination of ADT and external beam radiotherapy?
- 5 6. What is the clinical and cost effectiveness of docetaxel in combination  
6 with ADT in people with non-metastatic prostate cancer?
- 7 7. What is the clinical and cost effectiveness of abiraterone in combination  
8 with prednisolone in people with non-metastatic prostate cancer?

9 **Management options after radical treatment for people with**  
10 **non-metastatic prostate cancer and high-risk features for**  
11 **recurrence**

- 12 8. What is the clinical and cost effectiveness of immediate post-operative  
13 radiotherapy versus delayed post-operative radiotherapy in people with  
14 non-metastatic prostate cancer with high-risk features for recurrence?
- 15 9. What is the clinical and cost effectiveness of adjuvant ADT and  
16 radiotherapy versus radiotherapy in people with non-metastatic prostate  
17 cancer and high-risk features for recurrence?

18 **Adapting recommendations from NHS England**

19 We will consider adapting recommendations from [NHS England's clinical](#)  
20 [commissioning policy on abiraterone acetate and prednisolone for high-risk,](#)  
21 [hormone sensitive, non-metastatic prostate cancer \(adults\)](#). As part of this, we  
22 will assess the systematic reviews used to inform the policy.

23 We will also consider:

- 24 • the estimated costs or savings associated with the recommendations  
25 (resource impact)
- 26 • availability and implementation within the NHS
- 27 • health economics

- 1 • health inequalities
- 2 • whether the recommendations are within the scope of NICE's prostate
- 3 cancer guideline.

## 4 **Economic aspects**

5 We will take economic aspects into account when making recommendations.  
6 For each review question (or key areas in the scope), we review the economic  
7 evidence and, where appropriate, carry out economic modelling and analyses,  
8 to assess the value for money (cost effectiveness) of interventions. This is  
9 done using an NHS and personal social services perspective.

## 10 **NICE guidance and quality standards that may be** 11 **affected by this update**

- 12 • High-intensity focused ultrasound for prostate cancer (2005). NICE  
13 interventional procedures guidance 118
- 14 • Focal therapy using high-intensity focused ultrasound for localised prostate  
15 cancer (2023). NICE interventional procedures guidance 756
- 16 • Prostate cancer (2021). NICE quality standard 91

## 17 **Incorporating NICE technology appraisals**

18 NICE technology appraisal guidance will be incorporated into the guideline  
19 where relevant. For further details, see our [web page on bringing our](#)  
20 [guidance together by topic](#).

21 NICE's current, or in development, technology appraisals are:

- 22 • [Talazoparib with enzalutamide for untreated hormone-relapsed metastatic](#)  
23 [prostate cancer](#) (2026). NICE technology appraisal guidance 1130
- 24 • [Abiraterone \(originator and generics\) for treating newly diagnosed high-risk](#)  
25 [hormone-sensitive metastatic prostate cancer](#) (2025). NICE technology  
26 appraisal guidance 1110

- 1 • [Darolutamide with androgen deprivation therapy for treating hormone-](#)  
2 [sensitive metastatic prostate cancer](#) (2025). NICE technology appraisal  
3 guidance 1109
  - 4 • [Relugolix for treating hormone-sensitive prostate cancer](#) (2024). NICE  
5 technology appraisal guidance 995
  - 6 • [Olaparib with abiraterone for untreated hormone-relapsed metastatic](#)  
7 [prostate cancer](#) (2024). NICE technology appraisal guidance 951
  - 8 • [Darolutamide with androgen deprivation therapy and docetaxel for treating](#)  
9 [hormone-sensitive metastatic prostate cancer](#) (2023). NICE technology  
10 appraisal guidance 903
  - 11 • [Olaparib for previously treated BRCA mutation-positive hormone-relapsed](#)  
12 [metastatic prostate cancer](#) (2023). NICE technology appraisal guidance  
13 887
  - 14 • [Apalutamide with androgen deprivation therapy for treating hormone-](#)  
15 [sensitive metastatic prostate cancer](#) (2021). NICE technology appraisal  
16 guidance 741
  - 17 • [Apalutamide with androgen deprivation therapy for treating high-risk](#)  
18 [hormone-relapsed non-metastatic prostate cancer](#) (2021). NICE technology  
19 appraisal guidance 740
  - 20 • [Enzalutamide for treating hormone-sensitive metastatic prostate cancer](#)  
21 (2021). NICE technology appraisal guidance 712
  - 22 • [Larotrectinib for treating NTRK fusion-positive solid tumours](#) (2020). NICE  
23 technology appraisal guidance 630
  - 24 • [Enzalutamide for hormone-relapsed non-metastatic prostate cancer](#) (2019).  
25 NICE technology appraisal guidance 580
  - 26 • [Padeliporfin for untreated localised prostate cancer](#) (2018). NICE  
27 technology appraisal guidance 546
  - 28 • [Radium-223 dichloride for treating hormone-relapsed prostate cancer with](#)  
29 [bone metastases](#) (2016). NICE technology appraisal guidance 412
  - 30 • [Degarelix for treating advanced hormone-dependent prostate cancer](#)  
31 (2016). NICE technology appraisal guidance 404
  - 32 • [Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with](#)  
33 [docetaxel](#) (2016). NICE technology appraisal guidance 391
- NICE guideline update: [prostate cancer: diagnosis and management](#)

- 1 • [Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated](#) (2016). NICE technology appraisal  
2 guidance 387
- 3
- 4 • [Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated](#) (2016). NICE technology appraisal  
5 guidance 377
- 6
- 7 • [Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen](#) (2014). NICE technology  
8 appraisal guidance 316
- 9
- 10 • [Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours](#) (2012). NICE technology appraisal  
11 guidance 265
- 12
- 13 • [Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen](#) (2012). NICE technology  
14 appraisal guidance 259
- 15
- 16 • [Docetaxel for the treatment of hormone-refractory metastatic prostate cancer](#) (2006). NICE technology appraisal guidance 101.  
17

## 18 Further information

The guideline update is expected to be published in **month year**.

To follow the progress of the update, see the [guideline in development page](#) ([link to page](#)).

Our website has information about [how NICE guidelines are developed](#).

19

20 NICE guidelines cover health and care in England. Decisions on how they  
21 apply in other UK countries are made by ministers in the [Welsh Government](#),  
22 [Scottish Government](#) and [Northern Ireland Executive](#).

23 © NICE **year**. All rights reserved. Subject to [Notice of rights](#).